Dermatology News and Research RSS Feed - Dermatology News and Research

Dermatology is the branch of medicine dealing with the skin and its diseases. Dermatologists take care of diseases and cancers of the skin, scalp, hair, and nails.
Dermatology expert to deliver presentation at 2015 ODAC

Dermatology expert to deliver presentation at 2015 ODAC

A leader in the specialty of cosmetic dermatology, Dr. Leslie Baumann of Miami, Florida will be a featured speaker at the Orlando Dermatology Aesthetic & Clinical Conference (ODAC) in Orlando January 16-19, 2015. [More]
Valeant to redeem US$445.0M aggregate principal amount of 6.875% Senior Notes due 2018

Valeant to redeem US$445.0M aggregate principal amount of 6.875% Senior Notes due 2018

Valeant Pharmaceuticals International, Inc. today announced that its wholly owned subsidiary, Valeant Pharmaceuticals International, will redeem US$445.0 million aggregate principal amount of its outstanding 6.875% Senior Notes due 2018, CUSIP Nos. 91911XAN4, U9098VAF9 (the "Notes") on December 29, 2014 and has mailed an irrevocable notice of redemption for the Notes. [More]
Infections due to Staphylococcus aureus bacterium aggravate neurodermatitis

Infections due to Staphylococcus aureus bacterium aggravate neurodermatitis

Because the skin and its function as a barrier are severely compromised in neurodermatitis patients, a large number of bacterial species are able to multiply - including the bacterium Staphylococcus aureus. [More]
Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

Auxilium Pharmaceuticals presents STENDRA clinical data for ED treatment at SMSNA Scientific Meeting

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that data were presented regarding the use of STENDRA® (avanafil) tablets for the treatment of erectile dysfunction (ED) at the 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA) held in Miami from November 20-23, 2014. [More]
Scientists use TPF-SHG microscopy to study effects of micro-ablative fractional laser resurfacing

Scientists use TPF-SHG microscopy to study effects of micro-ablative fractional laser resurfacing

Many people in the Western World consider it as a social need to hide the effects of aging. For this purpose, different cutaneous rejuvenation treatments have been developed, including a laser-based technique, known as laser resurfacing. [More]

New, non-surgical approach to improve sagging skin in the chin and neck region

Patients looking for a non-surgical approach to treat unwanted sagging skin in the chin and neck region have a new and effective option. Bowes Dermatology is proud to offer patients the revolutionary Velashape III to address this common concern. [More]
Valeant Pharmaceuticals hosts ribbon-cutting ceremony to celebrate renovation of U.S. headquarters in NJ

Valeant Pharmaceuticals hosts ribbon-cutting ceremony to celebrate renovation of U.S. headquarters in NJ

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today celebrated the completion of renovations to its U.S. headquarters in Bridgewater, New Jersey with a ribbon-cutting ceremony. [More]
New anti-cancer drug may protect normal cells against radiation

New anti-cancer drug may protect normal cells against radiation

Although radiation treatments have become much more refined in recent years, it remains a challenge to both sufficiently dose the tumor while sparing the surrounding tissue. [More]
Metabolic syndrome screening in bipolar disorder warranted

Metabolic syndrome screening in bipolar disorder warranted

The frequency of the metabolic syndrome in patients with bipolar disorder warrants systematic screening, say researchers, particularly among men, older patients and those receiving atypical antipsychotic treatment. [More]
Research finding could lead to new therapies for preventing growth of plexiform neurofibromas

Research finding could lead to new therapies for preventing growth of plexiform neurofibromas

UT Southwestern Medical Center researchers have determined the specific type of cell that gives rise to large, disfiguring tumors called plexiform neurofibromas, a finding that could lead to new therapies for preventing growth of these tumors. [More]
Study suggests possible link between body fat and risk of immunotherapy toxicity

Study suggests possible link between body fat and risk of immunotherapy toxicity

Immunotherapy that can be effective against tumors in young, thin mice can be lethal to obese ones, a new study by UC Davis researchers has found. [More]
Study reports IL-37's activity in the adaptive immune system

Study reports IL-37's activity in the adaptive immune system

A University of Colorado Cancer Center study published in this month's Proceedings of the National Academy of Sciences describes the activity of a recently discovered communication molecule of the body's immune system, Interleukin 37 or IL-37. It has been known to limit inflammation and the current study reports its activity in the adaptive immune system: IL-37 inhibits the ability of the immune system to recognize and target new antigens. [More]
UC Davis researchers link increased body fat and lethal drug reactions in mice

UC Davis researchers link increased body fat and lethal drug reactions in mice

Immunotherapy that can be effective against tumors in young, thin mice can be lethal to obese ones, a new study by UC Davis researchers has found. The findings, published online today in The Journal of Experimental Medicine, suggest a possible link between body fat and the risk of toxicity from some types of immunotherapy. [More]
Adults with eczema at greater risk of accidental bone fractures, other injuries

Adults with eczema at greater risk of accidental bone fractures, other injuries

Intense itching and dry, irritable skin aren't the only problems adults with eczema face. They are at greater risk of accidental bone fractures and other injuries, a new Northwestern Medicine® study has found. [More]
Auxilium Pharmaceuticals reports total revenues of $109.6 million for Q3 2014

Auxilium Pharmaceuticals reports total revenues of $109.6 million for Q3 2014

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced financial results for the third quarter ending September 30, 2014. [More]
New data demonstrates improved outcomes in psoriasis patients treated with Daivobet gel

New data demonstrates improved outcomes in psoriasis patients treated with Daivobet gel

Interim results from one of the largest and longest clinical trials ever conducted for a topical treatment in psoriasis showed that after eight weeks of treatment with calcipotriol/betamethasone dipropionate (Daivobet gel), the treatment was highly efficacious, preferred by patients and improved patients' and the physicians’ assessments of disease severity. [More]
Bortezomib drug effective against chronic GVHD

Bortezomib drug effective against chronic GVHD

Researchers at UC Davis have found that the drug bortezomib effectively treats chronic graft-versus-host disease (GVHD), a common and debilitating side effect from allogeneic hematopoietic stem cell transplants. [More]
Vascular receptor autoantibodies implicated in SSc-PAH

Vascular receptor autoantibodies implicated in SSc-PAH

medwireNews: Autoantibodies to endothelin receptor type A and angiotensin receptor type-1 predict the development of, and mortality from, systemic sclerosis-associated pulmonary arterial hypertension, research suggests. [More]

HRQoL goals may improve outcome in PAH

Health-related quality of life before and during treatment for pulmonary arterial hypertension is significantly associated with survival, Brazilian researchers report. [More]
Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications. [More]